Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open-label Adalimumab Clear all
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 30, 2026, 10:45 PM EDT
Terminated Phase 4 Interventional Results available

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

NCT01543204
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 30, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 30, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

NCT00690911
View directory record Official record
Conditions
Sarcoidosis
Interventions
adalimumab
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

NCT00195715
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
63
States / cities
Huntsville, Alabama • Jacksonville, Alabama • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Remission in Subjects With Crohn's Disease, 1 Year Phase

NCT00055497
View directory record Official record
Conditions
Crohn's Disease
Interventions
Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
43
States / cities
Berkeley, California • Long Beach, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

NCT02489227
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
CHS-1420, Adalimumab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
28
States / cities
Phoenix, Arizona • Encino, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

NCT02640612
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

NCT02198651
View directory record Official record
Conditions
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 30, 2026, 10:45 PM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

NCT00731757
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
Humira
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Open-Label Adalimumab for Ulcerative Colitis Patients

NCT00421642
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 30, 2026, 10:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

NCT03153319
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions
Adalimumab Injection [Humira], Saline Solution for Injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

NCT02675023
View directory record Official record
Conditions
Healthy
Interventions
M923
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

NCT00195663
View directory record Official record
Conditions
Early Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
31
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02114931
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 501
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 81 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Huntsville, Alabama • Peoria, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

A Study of Adalimumab to Treat Sarcoidosis of the Skin

NCT00274352
View directory record Official record
Conditions
Sarcoidosis
Interventions
adalimumab
Drug
Lead sponsor
Pariser, Robert J., M.D.
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)

NCT02332590
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Covina, California • Long Beach, California • Whittier, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis - Extension Study

NCT01866592
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 30, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Study of Adalimumab in Patients With Axial Spondyloarthritis

NCT00939003
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Adalimumab, Placebo, Open-label Adalimumab
Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 30, 2026, 10:45 PM EDT
Completed Phase 4 Interventional Results available

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

NCT02092467
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
tofacitinib, adalimumab, etanercept
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
4,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
142
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 30, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

NCT00298272
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate
Biological · Drug · Dietary Supplement
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
18
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 30, 2026, 10:45 PM EDT